Neil Kumar, Chief Executive Officer at BridgeBio Pharma, Inc. (BBIO), sold 75,000 shares at $36.87 ($2.8M) on 2025-03-25, disclosed to the SEC on 2025-03-27.
Scheduled sale ($2.8M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| BBIO | SELL | 2026-06-08 | $4.6M | — | Filing → |
| BBIO | SELL | 2026-05-26 | $1.8M | — | Filing → |
| BBIO | SELL | 2026-05-11 | $5.3M | — | Filing → |